HRP20000903A2 - Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties - Google Patents

Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties Download PDF

Info

Publication number: HRP20000903A2
Authority: HR; Croatia
Prior art keywords: alkyl; alkyloxy; amino; methyl; hydroxy
Prior art date: 1998-07-06

Application number

HR20000903A

Other languages

English (en)

Croatian (hr)

Inventor

Robert

Wim

David

Walter

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-06

Filing date

2000-12-28

Publication date

2001-12-31

2000-12-28 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2001-12-31 Publication of HRP20000903A2 publication Critical patent/HRP20000903A2/hr

Links

239000003528 protein farnesyltransferase inhibitor Substances 0.000 title claims description 21
238000001727 in vivo Methods 0.000 title claims description 13
230000000637 radiosensitizating effect Effects 0.000 title claims description 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 234
239000001257 hydrogen Substances 0.000 claims description 100
229910052739 hydrogen Inorganic materials 0.000 claims description 100
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 92
150000001875 compounds Chemical class 0.000 claims description 71
-1 4,4-dimethyloxazolyl Chemical group 0.000 claims description 57
229910052736 halogen Inorganic materials 0.000 claims description 44
150000002367 halogens Chemical class 0.000 claims description 44
206010028980 Neoplasm Diseases 0.000 claims description 32
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 23
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
239000002253 acid Substances 0.000 claims description 21
125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 21
150000003839 salts Chemical class 0.000 claims description 21
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 20
125000004093 cyano group Chemical group *C#N 0.000 claims description 17
239000000825 pharmaceutical preparation Substances 0.000 claims description 15
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 12
125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 11
125000004951 trihalomethoxy group Chemical group 0.000 claims description 11
125000004953 trihalomethyl group Chemical group 0.000 claims description 11
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 10
230000005855 radiation Effects 0.000 claims description 10
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
150000001413 amino acids Chemical class 0.000 claims description 8
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
125000002883 imidazolyl group Chemical group 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
239000001301 oxygen Substances 0.000 claims description 8
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical group FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 7
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 6
101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims description 6
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
229910052717 sulfur Chemical group 0.000 claims description 6
239000011593 sulfur Chemical group 0.000 claims description 6
125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
230000005865 ionizing radiation Effects 0.000 claims description 3
PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 claims description 3
WOYOASASOHZEDR-UHFFFAOYSA-N 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-hydroxy-(3-methylimidazol-4-yl)methyl]-1-methylquinolin-2-one Chemical compound CN1C=NC=C1C(O)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 WOYOASASOHZEDR-UHFFFAOYSA-N 0.000 claims description 2
ZMLMGCPNMBRTKN-UHFFFAOYSA-N 6-[(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-ethoxyphenyl)-1-methylquinolin-2-one;hydrate;hydrochloride Chemical compound O.Cl.CCOC1=CC=CC(C=2C3=CC(=CC=C3N(C)C(=O)C=2)C(C=2N(C=NC=2)C)C=2C=CC(Cl)=CC=2)=C1 ZMLMGCPNMBRTKN-UHFFFAOYSA-N 0.000 claims description 2
PLHJCIYEEKOWNM-UHFFFAOYSA-N 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1C(N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-UHFFFAOYSA-N 0.000 claims description 2
ALKQAQOKGRWMSJ-UHFFFAOYSA-N 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-ethoxyphenyl)-1-methylquinolin-2-one Chemical compound CCOC1=CC=CC(C=2C3=CC(=CC=C3N(C)C(=O)C=2)C(N)(C=2N(C=NC=2)C)C=2C=CC(Cl)=CC=2)=C1 ALKQAQOKGRWMSJ-UHFFFAOYSA-N 0.000 claims description 2
206010070834 Sensitisation Diseases 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000000034 method Methods 0.000 claims description 2
238000011275 oncology therapy Methods 0.000 claims description 2
230000008313 sensitization Effects 0.000 claims description 2
150000003254 radicals Chemical class 0.000 description 36
238000002360 preparation method Methods 0.000 description 17
239000000203 mixture Substances 0.000 description 10
239000000243 solution Substances 0.000 description 9
239000002585 base Substances 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
229940024606 amino acid Drugs 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
239000002674 ointment Substances 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
102000004357 Transferases Human genes 0.000 description 4
108090000992 Transferases Proteins 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
239000000654 additive Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
238000009472 formulation Methods 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000009466 transformation Effects 0.000 description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
206010061902 Pancreatic neoplasm Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000009471 action Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
201000002528 pancreatic cancer Diseases 0.000 description 3
208000008443 pancreatic carcinoma Diseases 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000001235 sensitizing effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
IKMMPHALUZQNMN-UHFFFAOYSA-N 3-(1h-imidazol-5-ylmethyl)-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1CC1=CN=CN1 IKMMPHALUZQNMN-UHFFFAOYSA-N 0.000 description 2
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
150000001447 alkali salts Chemical group 0.000 description 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229940125846 compound 25 Drugs 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000003380 propellant Substances 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
125000006024 2-pentenyl group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
206010048832 Colon adenoma Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010016935 Follicular thyroid cancer Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010023347 Keratoacanthoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
206010004398 benign neoplasm of skin Diseases 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000011777 magnesium Chemical class 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000011591 potassium Chemical class 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000002453 shampoo Substances 0.000 description 1
239000011734 sodium Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012453 solvate Substances 0.000 description 1
235000014347 soups Nutrition 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
239000004474 valine Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Plural Heterocyclic Compounds (AREA)

HR20000903A 1998-07-06 2000-12-28 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties HRP20000903A2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP98202257		1998-07-06
EP98204330		1998-12-18
PCT/EP1999/004545 WO2000001411A1 (en)	1998-07-06	1999-06-30	Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Publications (1)

Publication Number	Publication Date
HRP20000903A2 true HRP20000903A2 (en)	2001-12-31

Family

ID=26150503

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20000903A HRP20000903A2 (en)	1998-07-06	2000-12-28	Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Country Status (31)

Country	Link
US (1)	US6545020B1 (xx)
EP (1)	EP1094839B1 (xx)
JP (1)	JP4530537B2 (xx)
KR (1)	KR100591603B1 (xx)
CN (1)	CN1152716C (xx)
AP (1)	AP1599A (xx)
AT (1)	ATE238811T1 (xx)
AU (1)	AU762423B2 (xx)
BG (1)	BG64941B1 (xx)
BR (1)	BR9911861A (xx)
CA (1)	CA2336624C (xx)
CZ (1)	CZ300968B6 (xx)
DE (1)	DE69907461T2 (xx)
DK (1)	DK1094839T3 (xx)
EA (1)	EA003877B1 (xx)
EE (1)	EE04582B1 (xx)
ES (1)	ES2199579T3 (xx)
HK (1)	HK1034451A1 (xx)
HR (1)	HRP20000903A2 (xx)
HU (1)	HU229076B1 (xx)
ID (1)	ID26987A (xx)
IL (2)	IL140721A0 (xx)
MY (1)	MY126519A (xx)
NO (1)	NO328178B1 (xx)
PL (1)	PL193464B1 (xx)
PT (1)	PT1094839E (xx)
SI (1)	SI1094839T1 (xx)
SK (1)	SK284723B6 (xx)
TR (1)	TR200003879T2 (xx)
TW (1)	TW586937B (xx)
WO (1)	WO2000001411A1 (xx)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69912790T2 (de)	1998-07-06	2004-09-23	Janssen Pharmaceutica N.V.	Farnesyl protein transferase inhibitoren zur behandlung von arthropathien
CN1152716C (zh)	1998-07-06	2004-06-09	詹森药业有限公司	具体***线感受性的法呢基蛋白质转移酶抑制剂
ATE323474T1 (de) *	2000-02-04	2006-05-15	Janssen Pharmaceutica Nv	Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
JO2361B1 (en)	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
DE60118225T2 (de)	2000-09-25	2007-05-03	Janssen Pharmaceutica N.V.	Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
WO2002024686A2 (en)	2000-09-25	2002-03-28	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
EP1322644A1 (en)	2000-09-25	2003-07-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
EP1322636A1 (en)	2000-09-25	2003-07-02	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
ATE434615T1 (de)	2000-11-21	2009-07-15	Janssen Pharmaceutica Nv	Farnesyltransferase hemmende benzoheterocyclische derivate
ES2260316T3 (es)	2000-12-27	2006-11-01	Janssen Pharmaceutica N.V.	Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
ES2263684T3 (es) *	2000-12-27	2006-12-16	Janssen Pharmaceutica N.V.	Derivados de 4-heterociclil-quinolina y -quinazolina que inhiben la farnesil transferasa.
EP1408971A4 (en)	2001-06-21	2006-01-25	Ariad Pharma Inc	NEW QUINOLINES AND THEIR USES
US7408063B2 (en)	2001-12-19	2008-08-05	Janssen Pharmaceutica, N.V.	1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ATE364384T1 (de)	2002-03-22	2007-07-15	Janssen Pharmaceutica Nv	Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
ATE336496T1 (de)	2002-04-15	2006-09-15	Janssen Pharmaceutica Nv	Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
EP1691812A4 (en)	2003-11-20	2010-01-13	Childrens Hosp Medical Center	GTPASE INHIBITORS AND METHOD OF USE
SG150533A1 (en) *	2003-11-20	2009-03-30	Janssen Pharmaceutica Nv	6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
US20070293539A1 (en) *	2004-03-18	2007-12-20	Lansbury Peter T	Methods for the treatment of synucleinopathies
CA2559221A1 (en) *	2004-03-18	2005-09-29	Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
JP2007529555A (ja) *	2004-03-18	2007-10-25	ザブライハムアンドウイメンズホスピタル，インコーポレイテッド	シヌクレイノパチーを治療する方法
WO2005089502A2 (en) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
US20050272068A1 (en) *	2004-03-18	2005-12-08	The Brigham And Women's Hospital, Inc.	UCH-L1 expression and cancer therapy
WO2005089515A2 (en) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
US20060194821A1 (en) *	2005-02-18	2006-08-31	The Brigham And Women's Hospital, Inc.	Compounds inhibiting the aggregation of superoxide dismutase-1
AU2006275528B2 (en)	2005-07-29	2012-03-08	Children's Hospital Medical Center	GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
EP2545919A1 (en)	2005-12-23	2013-01-16	Link Medicine Corporation	Treatment of synucleinopathies
DK2160386T3 (da) *	2007-05-23	2012-08-27	Allergan Inc	Terapeutiske ((phenyl)imidazolyl)methylquinolinylforbindelser
US8232402B2 (en) *	2008-03-12	2012-07-31	Link Medicine Corporation	Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2138844B1 (en)	2008-06-26	2012-04-25	SpheroTec GmbH	Method for testing the response of cells to exposures with therapeutics
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
BRPI0920927A2 (pt) *	2008-11-13	2019-09-24	Link Medicine Corp	derivados de azaquinolinona e usos dos mesmos
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US9980942B2 (en)	2012-05-02	2018-05-29	Children's Hospital Medical Center	Rejuvenation of precursor cells
CA2888485C (en)	2012-10-16	2021-01-26	Janssen Pharmaceutica Nv	Phenyl linked quinolinyl modulators of ror.gamma.t
RS56283B1 (sr)	2012-10-16	2017-12-29	Janssen Pharmaceutica Nv	Metilen vezani hinolinil modulatori ror-gama-t
EP2909189B8 (en)	2012-10-16	2017-04-19	Janssen Pharmaceutica NV	Heteroaryl linked quinolinyl modulators of ror-gamma-t
ES2742843T3 (es)	2013-10-15	2020-02-17	Janssen Pharmaceutica Nv	Moduladores de quinolinilo de ROR(gamma)t
US9284308B2 (en)	2013-10-15	2016-03-15	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en)	2013-10-15	2020-02-11	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORγt
AU2014334619A1 (en)	2013-10-15	2016-04-21	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORyt
US9221804B2 (en)	2013-10-15	2015-12-29	Janssen Pharmaceutica Nv	Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en)	2013-10-15	2016-05-03	Janssen Pharmaceutica Nv	Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en)	2013-10-15	2016-08-02	Janssen Pharmaceutica Nv	Phenyl linked quinolinyl modulators of RORγt
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
PT3277842T (pt)	2015-08-17	2019-09-05	Kura Oncology Inc	Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
WO2017184968A1 (en)	2016-04-22	2017-10-26	Kura Oncology, Inc.	Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
LT3534885T (lt)	2016-11-03	2021-07-12	Kura Oncology, Inc.	Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
US9956215B1 (en)	2017-02-21	2018-05-01	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2018156609A1 (en)	2017-02-21	2018-08-30	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (es)	2017-08-07	2020-03-20	Kura Oncology Inc	Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
US10806730B2 (en)	2017-08-07	2020-10-20	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
CN113286591A (zh)	2018-11-01	2021-08-20	库拉肿瘤学公司	用法尼基转移酶抑制剂治疗癌症的方法
US20220142983A1 (en)	2019-03-01	2022-05-12	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
TW202108170A (zh)	2019-03-15	2021-03-01	美商庫拉腫瘤技術股份有限公司	以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
TW202043487A (zh)	2019-03-29	2020-12-01	美商庫拉腫瘤技術股份有限公司	以法尼基轉移酶(farnesyltransferase)抑制劑治療鱗狀細胞癌之方法
WO2020205387A1 (en)	2019-04-01	2020-10-08	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en)	2019-05-02	2022-09-29	Kura Oncology, Inc.	Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5141851A (en) *	1990-04-18	1992-08-25	Board Of Regents, The University Of Texas System	Isolated farnesyl protein transferase enzyme
US6083917A (en) *	1990-04-18	2000-07-04	Board Of Regents, The University Of Texas System	Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5602184A (en) *	1993-03-03	1997-02-11	The United States Of America As Represented By Department Of Health And Human Services	Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
ES2175137T3 (es)	1995-12-08	2002-11-16	Janssen Pharmaceutica Nv	Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de laproteina farnesil-transferasa.
US20020034725A1 (en) *	1996-04-15	2002-03-21	W. Gillies Mckenna	Sensitization of cells to radiation and and chemotherapy
AU709409B2 (en) *	1996-07-15	1999-08-26	Bristol-Myers Squibb Company	Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
TW591030B (en)	1997-03-10	2004-06-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CN1152716C (zh)	1998-07-06	2004-06-09	詹森药业有限公司	具体***线感受性的法呢基蛋白质转移酶抑制剂
WO2000047574A1 (en) *	1999-02-11	2000-08-17	Pfizer Products Inc.	Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents

1999
- 1999-06-30 CN CNB998082678A patent/CN1152716C/zh not_active Expired - Lifetime
- 1999-06-30 EE EEP200000794A patent/EE04582B1/xx unknown
- 1999-06-30 PL PL99347979A patent/PL193464B1/pl unknown
- 1999-06-30 HU HU0103689A patent/HU229076B1/hu unknown
- 1999-06-30 WO PCT/EP1999/004545 patent/WO2000001411A1/en active IP Right Grant
- 1999-06-30 US US09/743,130 patent/US6545020B1/en not_active Expired - Lifetime
- 1999-06-30 TR TR2000/03879T patent/TR200003879T2/xx unknown
- 1999-06-30 EA EA200100111A patent/EA003877B1/ru not_active IP Right Cessation
- 1999-06-30 EP EP99931229A patent/EP1094839B1/en not_active Expired - Lifetime
- 1999-06-30 ES ES99931229T patent/ES2199579T3/es not_active Expired - Lifetime
- 1999-06-30 AU AU47805/99A patent/AU762423B2/en not_active Expired
- 1999-06-30 KR KR1020007014066A patent/KR100591603B1/ko not_active IP Right Cessation
- 1999-06-30 PT PT99931229T patent/PT1094839E/pt unknown
- 1999-06-30 JP JP2000557857A patent/JP4530537B2/ja not_active Expired - Lifetime
- 1999-06-30 BR BR9911861-0A patent/BR9911861A/pt not_active Application Discontinuation
- 1999-06-30 DK DK99931229T patent/DK1094839T3/da active
- 1999-06-30 ID IDW20010020A patent/ID26987A/id unknown
- 1999-06-30 CA CA002336624A patent/CA2336624C/en not_active Expired - Lifetime
- 1999-06-30 CZ CZ20004777A patent/CZ300968B6/cs not_active IP Right Cessation
- 1999-06-30 IL IL14072199A patent/IL140721A0/xx active IP Right Grant
- 1999-06-30 SI SI9930332T patent/SI1094839T1/xx unknown
- 1999-06-30 AT AT99931229T patent/ATE238811T1/de active
- 1999-06-30 AP APAP/P/2001/002057A patent/AP1599A/en active
- 1999-06-30 DE DE69907461T patent/DE69907461T2/de not_active Expired - Lifetime
- 1999-06-30 SK SK1986-2000A patent/SK284723B6/sk not_active IP Right Cessation
- 1999-07-01 MY MYPI99002794A patent/MY126519A/en unknown
- 1999-07-05 TW TW088111346A patent/TW586937B/zh not_active IP Right Cessation
2000
- 2000-12-28 HR HR20000903A patent/HRP20000903A2/hr not_active Application Discontinuation
2001
- 2001-01-03 BG BG105108A patent/BG64941B1/bg unknown
- 2001-01-04 IL IL140721A patent/IL140721A/en not_active IP Right Cessation
- 2001-01-05 NO NO20010082A patent/NO328178B1/no not_active IP Right Cessation
- 2001-07-18 HK HK01105023A patent/HK1034451A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
ATE238811T1 (de)	2003-05-15
PL347979A1 (en)	2002-05-06
SK19862000A3 (sk)	2001-12-03
DE69907461D1 (de)	2003-06-05
ID26987A (id)	2001-02-22
EE04582B1 (et)	2006-02-15
CA2336624C (en)	2008-10-21
NO328178B1 (no)	2009-12-28
CA2336624A1 (en)	2000-01-13
EA200100111A1 (ru)	2001-06-25
CZ300968B6 (cs)	2009-09-30
AP1599A (en)	2006-04-27
AU762423B2 (en)	2003-06-26
AU4780599A (en)	2000-01-24
IL140721A0 (en)	2002-02-10
JP4530537B2 (ja)	2010-08-25
US6545020B1 (en)	2003-04-08
HUP0103689A2 (hu)	2002-02-28
SK284723B6 (sk)	2005-10-06
MY126519A (en)	2006-10-31
HUP0103689A3 (en)	2003-01-28
EA003877B1 (ru)	2003-10-30
IL140721A (en)	2008-11-26
EP1094839A1 (en)	2001-05-02
SI1094839T1 (en)	2003-12-31
NO20010082L (no)	2001-01-05
DE69907461T2 (de)	2004-02-19
KR20010052770A (ko)	2001-06-25
EP1094839B1 (en)	2003-05-02
ES2199579T3 (es)	2004-02-16
WO2000001411A1 (en)	2000-01-13
AP2001002057A0 (en)	2001-03-31
PL193464B1 (pl)	2007-02-28
PT1094839E (pt)	2003-09-30
JP2002519389A (ja)	2002-07-02
BG105108A (en)	2001-11-30
CN1311692A (zh)	2001-09-05
KR100591603B1 (ko)	2006-06-20
DK1094839T3 (da)	2003-08-18
HK1034451A1 (en)	2001-10-26
BR9911861A (pt)	2001-03-20
CZ20004777A3 (en)	2001-05-16
EE200000794A (et)	2002-06-17
TW586937B (en)	2004-05-11
BG64941B1 (bg)	2006-10-31
HU229076B1 (en)	2013-07-29
CN1152716C (zh)	2004-06-09
NO20010082D0 (no)	2001-01-05
TR200003879T2 (tr)	2007-01-22

Legal Events

Date	Code	Title	Description
2001-12-31	A1OB	Publication of a patent application
2002-06-06	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2005-05-05	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20050505 Year of fee payment: 7
2005-09-06	ODBI	Application refused

Publication	Publication Date	Title
HRP20000903A2 (en)	2001-12-31	Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
JP5491681B2 (ja)	2014-05-14	乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
CA2397558A1 (en)	2001-08-30	Dosing regimen
US20030022918A1 (en)	2003-01-30	Farnesyl protein transferase inhibitor combinations with an her2 antibody
JP2003525246A (ja)	2003-08-26	白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
JP2003525244A (ja)	2003-08-26	抗腫瘍性アルキル化剤とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
US20030186925A1 (en)	2003-10-02	Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
JP2003525238A (ja)	2003-08-26	抗腫瘍性ポドフィロトキシン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
JP2003525245A (ja)	2003-08-26	ファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
JP2003525237A (ja)	2003-08-26	抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
CA2397475A1 (en)	2001-09-07	Farnesyl protein transferase inhibitor combinations with vinca alkaloids
MXPA01000161A (en)	2001-09-07	Farnesyl protein transferase inhibitors with in vivo
ZA200100151B (en)	2002-01-07	Farnesyl protein transfease inhibitors with in vivo radiosensitizing properties.